Optimizing Management of Patients With Visual Impairments as a Result of Diabetic Macular Edema. Role and Place of the Anti-Vegf-Preparation Aflibercept

Oftalmologicheskii Zhurnal - Ukraine
doi 10.31288/oftalmolzh201634954
Full Text
Abstract

Available in full text

Categories
Ophthalmology
Date
Authors
Publisher

Ukrainian Society of Ophthalmologists

Related search

Effect of Intravitreal Aflibercept on Recalcitrant Diabetic Macular Edema

International Journal of Retina and Vitreous
Ophthalmology
2017English

Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema

Ophthalmology
Ophthalmology
2016English

Diabetic Macular Edema Treated With Intravitreal Aflibercept Injection After Treatment With Other Anti-Vegf Agents (SWAP-TWO Study): 6-Month Interim Analysis

International Journal of Retina and Vitreous
Ophthalmology
2019English

Effect of Anti-Vegf Therapy on the Structural State of the Retina in Diabetic Macular Edema

Бюллетень Восточно-Сибирского научного центра Сибирского отделения Российской академии медицинских наук
2016English

Ranibizumab in the Treatment of Patients With Visual Impairment Due to Diabetic Macular Edema

Clinical Ophthalmology
Ophthalmology
2011English

Optical Coherence Tomography Use for Estimation of the Efficacy of Anti VEGF Therapy in Diabetic Retinopathy and Diabetic Macular Edema.

The Professional Medical Journal
2019English

Pss5 - Vision-Related Quality of Life in Patients With Diabetic Macular Edema Treated With Intravitreal Aflibercept: The Aqua Study

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Cost-Effectiveness of Ranibizumab Versus Aflibercept in the Treatment of Visual Impairment Due to Diabetic Macular Edema: A UK Healthcare Perspective

ClinicoEconomics and Outcomes Research
Health PolicyEconomicsEconometricsFinance
2015English

Intravitreal Corticosteroids in the Management of Diabetic Macular Edema

Current Ophthalmology Reports
Ophthalmology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy